Home

FAQ

1.Where is Tengion headquartered?
2.What year was Tengion incorporated and in what state?
3.On what exchange is Tengion listed and under what stock symbol?
4.How can I purchase shares?
5.When does the fiscal year end?
6.Who is Tengion’s transfer agent?
7.Who are Tengion’s independent auditors?
8.Who is Tengion’s outside legal counsel?
9.Who should I contact if I have any questions?
1.Where is Tengion headquartered?
 Tengion is headquartered in Winston-Salem, North Carolina.

2.What year was Tengion incorporated and in what state?
 Tengion was incorporated in the State of Delaware on July 10, 2003.

3.On what exchange is Tengion listed and under what stock symbol?
 Tengion is traded on the OTC Markets under the symbol TNGN.

4.How can I purchase shares?
 Shares can be purchased through a stockbroker of your choice. Tengion does not have a direct stock purchase plan.

5.When does the fiscal year end?
 December 31

6.Who is Tengion’s transfer agent?
 Tengion's Transfer Agent and Registrar is American Stock Transfer and Trust Company (www.amstock.com; 800-937-5449)

7.Who are Tengion’s independent auditors?
  Ernst and Young
Two Commerce Square
2001 Market Street, Suite 4000
Philadelphia, PA 19103
(215) 448-5000

8.Who is Tengion’s outside legal counsel?
 Ropes & Gray LLP
Prudential Tower
800 Boylston Street
Boston, MA 02199
(617) 951-7000

9.Who should I contact if I have any questions?
 Brian Davis
Chief Financial Officer and Vice President, Finance
ir@tengion.com

Investor Resources
TNGN(Common Stock)
ExchangeOTC BB (US Dollar)
Price$0.54
Change (%)0.00 (0.00%)
Volume810
Data as of 06/19/13 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
What's New
June 12, 2013
Tengion to Participate in Panel Discussion at ISSCR 11th Annual Meeting
WINSTON-SALEM, N.C., June 12, 2013 /PRNewswire/ -- Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced that Dr. Tim Bertram, the Company's President of Research and Development and Chief Scientific Officer, will participate in a panel at the International Society for Stem Cell Research (ISSCR) 11th Annual Meeting being held June 12th-15th, 2013 in Boston, Massachusetts. Dr. Bertram will take part in a panel discussion titled "Disease-focused Research: From Bench t... 
May 15, 2013
Tengion Provides Business Update and Reports First Quarter 2013 Financial Results
-- Phase 1 trial of Neo-Kidney Augment™ on track for initiation in Sweden in second quarter of 2013 and in U.S. in fourth quarter of 2013 -- -- Actively recruiting for final three patients in Neo-Urinary Conduit™ trial -- WINSTON-SALEM, N.C., May 15, 2013 /PRNewswire/ -- Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today provided a business update and reported its financial results for the first quarter ended March 31, 2013. "We are very pleased to have achieved a sig...